REG - Syncona Limited - Syncona launches new gene therapy company Beacon

SynconaAnnouncement

12/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230612:nRSL3233Ca&default-theme=true

RNS Number : 3233C  Syncona Limited  12 June 2023

Syncona Limited

 

Syncona launches new gene therapy company Beacon Therapeutics with £96
million Series A financing

 

12 June 2023

 

·      Beacon Therapeutics launches as a leading ophthalmic gene therapy
company, created by combining Applied Genetic Technologies Corporation's
(AGTC's) late-stage X-linked retinitis pigmentosa (XLRP) programme with two
proprietary pre-clinical programmes

·      Syncona is leveraging its deep domain expertise and track record
to create its third gene therapy company addressing retinal diseases,
following Gyroscope and Nightstar

·      Syncona has committed £75 million to Beacon and will have a 65.3
per cent stake 1  (#_ftn1) in the business, with a current holding value of
£60 million 2  (#_ftn2)

 

Syncona Ltd, a leading healthcare company focused on creating, building and
scaling a portfolio of global leaders in life science, today announces that it
has launched Beacon Therapeutics Holdings Limited (Beacon Therapeutics), a
leading ophthalmic gene therapy company with a purpose to restore and improve
the vision of patients with retinal diseases, with a £96 million Series A
financing. The new portfolio company has been created by Syncona through the
combination of Applied Genetic Technologies Corporation's (AGTC's) late-stage
programme in X-linked retinitis pigmentosa (XLRP), with two other innovative
pre-clinical programmes.

 

Syncona's holding value in Beacon Therapeutics is £60 million, having
committed £75 million to the company, including the capital already invested
to acquire and restructure AGTC. Syncona has been supporting the company to
re-define its clinical plan, optimise its manufacturing plan for commercial
roll-out, restructure costs in the business, broaden the pipeline and expand
the team. At the point all current commitments are invested, Syncona will have
a 65.3 per cent stake in the business. Syncona led the financing round
alongside additional investors including Oxford Science Enterprises (OSE).

 

The Series A financing will be used to advance Beacon Therapeutics' gene
therapy candidates through to key value inflection points, including Beacon
Therapeutics' lead programme AGTC-501, which is currently in Phase II clinical
trials for the treatment of XLRP, an inherited monogenic disorder that leads
to progressive vision loss in males. AGTC-501 has a strong body of clinical
evidence having demonstrated meaningful efficacy and a good safety profile in
its recent Phase I/II HORIZON trial. 12-month data from its Phase II SKYLINE
trial is expected in H2 CY2023.

 

Beacon Therapeutics also has two promising pre-clinical programmes that
Syncona identified. The first asset is an intravitreally delivered gene
therapy for dry age-related macular degeneration (AMD), the leading cause of
blindness in people over 60, and the second has been in-licensed from the
University of Oxford and is targeting cone-rod dystrophy (CRD), a group of
inherited vision loss disorders affecting the retina. Syncona has combined
these assets with AGTC's later-stage asset in XLRP to create its third
ophthalmic gene therapy company, following Nightstar, which sold for $877
million, at a 4.5 multiple of cost, and Gyroscope, which was sold for up to
$1.5 billion, at a potential 5.1x multiple of cost.

 

David Fellows will lead Beacon Therapeutics as Chief Executive Officer (CEO),
bringing 40 years' experience in ophthalmology to the management team,
including five years as Nightstar's CEO. He will be joined by Chief Medical
Officer (CMO) Dr Nadia Waheed, a retinal expert and former Chief Medical
Officer of Gyroscope, and gene therapy expert Dr Abraham Scaria, who has
joined as Chief Scientific Officer. Syncona Investment Management Limited CEO,
Chris Hollowood, has been appointed as Chair and Syncona Lead Partner Elisa
Petris will be joining the Board as a Director. Professor Robert MacLaren,
Professor of Ophthalmology at the University of Oxford, will be an active
advisor on Beacon Therapeutics' CRD program and has also become a
non-executive director.

 

Chris Hollowood, Chief Executive Officer of Syncona Investment Management
Limited, said: "By acquiring AGTC and combining its late-stage programme with
highly complementary and innovative science from the University of Oxford and
elsewhere, we have created an exciting new gene therapy company in an area
where we have a great breadth and depth of knowledge and expertise. The
creation of this unique company demonstrates Syncona's creativity and the
proactive and proprietary nature of our approach to sourcing new
opportunities.

 

We have the opportunity to leverage our expertise, track record and network to
support Beacon Therapeutics as it develops gene therapies for people suffering
from debilitating inherited retinal diseases. We look forward to working
closely with Beacon Therapeutics' exceptional management team to advance these
assets through the clinic and towards patients."

 

David Fellows, Chief Executive Officer of Beacon Therapeutics, commented:
"Beacon Therapeutics combines a broad development pipeline, a deep scientific
foundation, a strong clinical network, and a highly experienced management
team to drive forward a unique late-stage clinical and pre-clinical pipeline.
With the 12-month data from our Phase II SKYLINE trial for AGTC-501 expected
shortly and two highly innovative and differentiated pipeline assets for
prevalent and rare blinding diseases, we are excited to be building a new
leader in the ophthalmic gene therapy space."

 

Professor Robert MacLaren, Professor of Ophthalmology, University of Oxford,
and Co-Founder of Beacon Therapeutics, commented: "I have dedicated many years
to translating pioneering gene therapies from the lab through to clinical
trial phase with the support of my team in the Nuffield Department of Clinical
Neurosciences and NIHR Oxford Biomedical Research Centre (BRC). Beacon
Therapeutics is quite unique in being a company that at launch is already
underpinned by excellent clinical trial data. The company has both highly
innovative retinal gene therapy programmes and the means to target them to the
main causes of blindness in both the young and old."

 

 ENDS 

 

Copies of this press release and other corporate information can be found on
the company website at: www.synconaltd.com (http://www.synconaltd.com)

 

Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of investments of
Syncona Limited. These statements and forecasts involve risk and uncertainty
because they relate to events and depend upon circumstances that may or may
not occur in the future. There are a number of factors that could cause actual
results or developments to differ materially from those expressed or implied
by these forward-looking statements. In particular, many companies in the
Syncona Limited portfolio are conducting scientific research and clinical
trials where the outcome is inherently uncertain and there is significant risk
of negative results or adverse events arising. In addition, many companies in
the Syncona Limited portfolio have yet to commercialise a product and their
ability to do so may be affected by operational, commercial and other risks.

 

Enquiries

 

Syncona Ltd

 

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

 

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.

 

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading healthcare
businesses for the benefit of all our stakeholders. We focus on developing
treatments for patients by working in close partnership with world-class
academic founders and management teams. Our balance sheet underpins our
strategy enabling us to take a long-term view as we look to improve the lives
of patients with no or poor treatment options, build sustainable life science
companies and deliver strong risk-adjusted returns to shareholders.

 

About Beacon Therapeutics

 

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to
restore and improve the vision of patients with a range of prevalent and rare
retinal diseases that result in blindness.

 

The Company has an established scientific foundation that combines a
late-stage development candidate to treat X-linked retinitis pigmentosa
(XLRP), as well as two preclinical programs, one targeting dry age-related
macular degeneration (AMD) and another in-licensed from the University of
Oxford targeting cone-rod dystrophy (CRD), an inherited retinal disease.

 

Lead development candidate AGTC-501, is a gene therapy program in Phase II
clinical trials for the treatment of XLRP, an inherited monogenic recessive
disorder that causes progressive vision loss in boys and young men. XLRP is
predominantly caused by mutations in the retinitis pigmentosa GTPase regulator
(RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby
addressing the full complement of photoreceptor damage caused by XLRP,
including both rod and cone loss.

 

Beacon Therapeutics also has access to a target generation technology platform
that will identify, screen and search secreted proteins in the ophthalmology
space.

 

The Company is supported by funds from Syncona and additional investors
including Oxford Science Enterprises.

 

Find out more about us online at: www.beacontx.com (http://www.beacontx.com) .

 

 1  (#_ftnref1) Percentage holding reflects Syncona's ownership stake at the
point full current commitments are invested.

 2  (#_ftnref2) Beacon is held by Syncona at price of recent investment. £60
million of total £75 million commitment has been invested to date

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUFLFVERAILLIV